AspenBio Pharma
(Nasdaq: APPY), an in vitro diagnostic company, today provided its
shareholders and the broader investment community with an update on its
clinical and business activities. The Company announced that it plans to
initiate a...

AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that the United States District Court for Colorado has dismissed and entered judgment without prejudice in both the class action lawsuit (Case No....

AspenBio Pharma, Inc. (Nasdaq: APPY) today announced that it has executed an exclusive worldwide license agreement with a major international animal health company, providing license and sub-license rights to AspenBio's entire animal health...

AspenBio Pharma, Inc. (NASDAQ: APPY) yesterday announced the pricing of an underwritten public offering of 6,100,000 shares of common stock at an offering price of $2.00 per share.
The number of shares and offering price reflect a one-for-six...

AspenBio Pharma,
Inc. (NASDAQ: APPY), announced today that it has entered into definitive agreements with
certain new and existing institutional investors to sell an aggregate
of 1,605,000 shares of its no par value common stock
and warrants to...

NEW YORK, Oct. 1, 2010 (GLOBE NEWSWIRE) -- The Rosen Law Firm today announced that it has filed a class action lawsuit on behalf of investors who purchased the common stock of AspenBio Pharma, Inc. ("AspenBio" or the "Company") (Nasdaq:APPY) between

The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.